KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Capital Leases: 2012

Historic Capital Leases for Halozyme Therapeutics (HALO) over the last 1 years, with Dec 2012 value amounting to $1.4 million.

  • Halozyme Therapeutics' Capital Leases was N/A to $2.5 million in Q3 2013 from the same period last year, while for Sep 2013 it was $2.5 million, marking a year-over-year change of. This contributed to the annual value of $1.4 million for FY2012, which is N/A change from last year.
  • Halozyme Therapeutics' Capital Leases amounted to $1.4 million in FY2012.
  • In the past 5 years, Halozyme Therapeutics' Capital Leases ranged from a high of $1.4 million in FY2012 and a low of $1.4 million during FY2012.
  • Moreover, its 1-year median value for Capital Leases was $1.4 million (2012), whereas its average is $1.4 million.